CHIR-99021 (Laduviglusib)

카탈로그 번호S1263 배치:S126308

인쇄

기술 자료

화학식

C22H18Cl2N8
분자량 465.34 CAS 번호 252917-06-9
용해도 (25°C)* 시험관 내(In vitro) DMSO 93 mg/mL (199.85 mM)
Water Insoluble
Ethanol Insoluble
생체 내(In Vivo) (개별적으로 순서대로 용매를 제품에 첨가하십시오.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml은 약간 용해되거나 불용해됨을 의미합니다.
* Selleck은 모든 화합물의 용해도를 자체적으로 테스트하며, 실제 용해도는 게시된 값과 약간 다를 수 있습니다. 이는 정상적인 현상이며, 약간의 배치 간 변동으로 인해 발생합니다.
* 실온 배송 (안정성 테스트 결과 이 제품은 냉각 조치 없이 배송될 수 있음을 보여줍니다.)

원액 준비

생물학적 활성

설명 Laduviglusib (CHIR-99021, CT99021)은 GSK-3α 및 GSK-3β 억제제로, IC50 값은 각각 10 nM 및 6.7 nM입니다. 이 화합물은 cyclin-dependent kinases(CDKs)에 대한 교차 반응성을 나타내지 않으며, CDKs 대비 GSK-3β에 대해 350배 높은 선택성을 보입니다. 이 화합물은 Wnt/beta-catenin 활성제로 기능하며 Autophagy를 유도합니다.
표적
GSK-3β
(Cell-free assay)		 GSK-3α
(Cell-free assay)
6.7 nM 10 nM
시험관 내(In vitro) CHIR-99021 (Laduviglusib) shows greater than 500-fold selectivity for GSK-3 versus its closest homologs CDC2 and ERK2, as well as other protein kinases. Furthermore, it shows only weak binding to a panel of 22 pharmacologically relevant receptors and little inhibitory activity against a panel of 23 nonkinase enzymes. This compound induces the activation of glycogen synthase (GS) in insulin receptor-expressing CHO-IR cells with EC50 of 0.763 μM.
생체 내(In Vivo) Oral administration of CHIR-99021 (Laduviglusib) at 30 mg/kg enhances glucose metabolism in a rodent model of type 2 diabetes, with a maximal plasma glucose reduction of nearly 150 mg/dl 3-4 hours after administration, while plasma insulin remains at or below control levels. When given orally at 16 or 48 mg/kg 1 hour before oral glucose challenges in ZDF rats, this compound significantly improves glucose tolerance with 14% and 33% reduction in plasma glucose at 16 mg/kg and 48 mg/kg, respectively; the higher dose also reduces hyperglycemia before the oral glucose challenge.

프로토콜 (참조)

세포 분석:

[1]
  • 세포주

    Insulin receptor–expressing CHO-IR cells; Primary rat hepatocytes

  • 농도

    0.01-10 μM

  • 배양 시간

    30 min

  • 방법

    CHIR-99021 (Laduviglusib) is used in the following procedure: CHO-IR cells expressing human insulin receptor are grown to 80% confluence in Hamm’s F12 medium with 10% fetal bovine serum and without hypoxanthine. Trypsinized cells are seeded in 6-well plates at 1 × 10⁶ cells/well in 2 ml of medium without fetal bovine serum. After 24 h, medium is replaced with 1 ml of serum-free medium containing this compound or control (final DMSO concentration <0.1%) for 30 min at 37°C. Cells are lysed and centrifuged 15 min at 4°C/14000g. The activity ratio of GS is calculated as the GS activity in the absence of glucose-6-phosphate divided by the activity in the presence of 5 mmol/l glucose-6-phosphate, using the filter paper assay of Thomas et al.
동물 연구:

[1]
  • 동물 모델

    Female db/db mice; Male ZDF rats

  • 용량

    8-48 mg/kg

  • 투여

    oral administration

참조

  • https://pubmed.ncbi.nlm.nih.gov/12606497/

고객 제품 검증

<p>For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of CHIR-99021 by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells. </p>

, , Dr. Yong-Weon Yi from Georgetown University Medical Center

Lu1205 were treated with protein kinase inhibitors. Cell cycle protein expression was analyzed by western blot.

데이터 출처 [ , , Med Oncol, 2017, 35(1):7 ]

Selleck's CHIR-99021 (Laduviglusib) 인용됨 1086 출판물

GLIS2 Promotes Epithelial-Mesenchymal Transition and Gastric Cancer Progression by Regulating BGN to Activate the Wnt/β-Catenin Pathway [ The Kaohsiung Journal of Medical Sciences, September 12, 2025, e70103]
Rapamycin and CHIR99021 Coordinate Robust Cardiomyocyte Differentiation From Human Pluripotent Stem Cells Via Reducing p53-Dependent Apoptosis [ Journal of the American Heart Association, October 2, 2017, e005295] PubMed: 28971953
The Glycogen Synthase Kinase-3 Inhibitor CHIR99021 Reduces Fatty Infiltration and Muscle Atrophy After Rotator Cuff Tears: An In Vitro Experiment and In Vivo Mouse Model [ The American Journal of Sports Medicine, February 24, 2025, 1184-1194]
Pre-adaptation of stem cell-derived islet organoids to hypoxia via zinc transportation inhibition drives angiogenesis [ Cell Stem Cell, 2026, 33(4):676-694.e10] PubMed: 41932324
Histone H3.3 phosphorylation facilitates H3K9me3-heterochromatin formation during retrotransposon silencing and X-chromosome inactivation via H3.3K27me3-CBX7-KAP1 axis [ Sci Bull (Beijing), 2026, 71(4):820-837] PubMed: 41582043
Neural crest cell-derived DKK1 and NEDD4 modulate Wnt signalling in the second heart field to orchestrate outflow tract development [ Nat Commun, 2026, 17(1):1751] PubMed: 41571667
Epitranscriptomic regulation of mRNA stability in pivotal transcription factors modulates the second cell fate decision [ Nat Commun, 2026, 17(1):5800] PubMed: 42045194
Modeling early human heart development using an iPSC-based 3D bioprinted model of embryonic heart tube [ Nat Commun, 2026, 17(1):5689] PubMed: 42031752
Unbalanced chromatin binding of Polycomb complexes drives neurodevelopmental disorders [ Mol Cell, 2026, 86(4):604-624.e16] PubMed: 41653922
Endogenous retroviral elements LTR8B and MER65 rewire PSG9 regulation to control trophoblast syncytialization and pre-eclampsia risk [ Genome Biol, 2026, 27(1)73] PubMed: 41796334

반품 정책
Selleck Chemical의 무조건 반품 정책은 고객에게 원활한 온라인 쇼핑 경험을 보장합니다. 구매에 어떤 식으로든 불만족하시면, 수령일로부터 7일 이내에 모든 품목을 반품하실 수 있습니다. 제품 품질 문제(프로토콜 관련 문제 또는 제품 관련 문제)가 발생하는 경우, 원래 구매일로부터 365일 이내에 모든 품목을 반품하실 수 있습니다. 제품 반품 시 아래 지침을 따르십시오.

배송 및 보관
Selleck 제품은 실온에서 운송됩니다. 실온에서 제품을 받으셨더라도 안심하십시오. Selleck 품질 검사 부서에서 한 달간의 상온 보관이 분말 제품의 생물학적 활성에 영향을 미치지 않음을 확인하는 실험을 수행했습니다. 수령 후, 데이터시트에 설명된 요구 사항에 따라 제품을 보관하십시오. 대부분의 Selleck 제품은 권장 조건에서 안정적입니다.

인간, 수의학 진단 또는 치료 용도로 사용하지 마십시오.